SCHEMBL25324075

SCHEMBL25324075

O=C(N1CC(NCc2cc(C(F)(F)F)ccc2Cl)C1)N1CC2(CC(c3nnc(C4CC4)[nH]3)C2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 2/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ PDE2A O00408 1/20 0.34
▸ TEAD1 P28347 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ FPR3 P25089 1/20 0.34
▸ FPR2 P25090 1/20 0.34
▸ CRHR1 P34998 3/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ TRAP1 Q12931 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ HSP90B1 P14625 1/20 0.33
▸ SCN9A Q15858 1/20 0.32
▸ PDCD1LG2 Q9BQ51 1/20 0.32
▸ CD274 Q9NZQ7 1/20 0.32
▸ CRHR2 Q13324 1/20 0.32
▸ SLC6A2 P23975 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25325226 0.93 FAAH (0.38) P2RX7KMT2AMEN1PDE2ATEAD1
SCHEMBL25322265 0.91 POLB (0.39) KMT2AMEN1PDE2ATEAD1FPR3
SCHEMBL25325835 0.89 MGLL (0.37) PDE2ATEAD1MGLLSLC6A4
SCHEMBL25325838 0.86 PDE2A (0.39) KMT2AMEN1PDE2ATEAD1SCN9A
SCHEMBL25325112 0.86 TEAD1 (0.44) TEAD1MGLL
SCHEMBL25325418 0.86 MGLL (0.36) KMT2AMEN1PDE2ATEAD1MGLL
SCHEMBL30553285 0.85 FAAH (0.36) P2RX7MGLLPDCD1LG2CD274
SCHEMBL25325576 0.85 FAAH (0.36) P2RX7MGLLPDCD1LG2CD274
SCHEMBL25324202 0.84 FAAH (0.38) TEAD1MGLL
SCHEMBL30553134 0.84 FAAH (0.38) TEAD1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 P2RX7 216/4885EPHX2 292/4885KMT2A 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback